Skip to main content

Janus Henderson Investors — Portfolio, Page 5

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

227
Companies
$31.3B
Total invested
$160.4M
Avg. check
15
Industries
Biotechnology 23Therapeutics 11Health Care 10Pharmaceutical 9Life Science 7Medical 7+9 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 97120 of 227
Diagonal Therapeutics
January 2026

Diagonal Therapeutics is a biotechnology startup that develops targeted therapies for cancer and genetic diseases.

Biopharma · Watertown$125.0M Series B
Phathom Pharmaceuticals
January 2026

Phathom Pharmaceuticals is a biopharmaceutical company.

Biotechnology · Florham Park$130.0M Post-IPO Equity
Synthekine
January 2023

Synthekine is a development stage biotherapeutics company focused on the engineering of novel specific and potent cytokine therapies.

Biotechnology · Menlo Park$100.0M Series C
Vaxcyte
January 2026

Vaxcyte focuses on developing vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide.

Biopharma · San Carlos$632.5M Post-IPO Equity
Structure Therapeutics
December 2025

Structure Therapeutics specializes in the discovery and development of drugs against a type of targets called GPCR.

Biotechnology · South San Francisco$747.5M Post-IPO Equity
Tenpoint Therapeutics
January 2026

Tenpoint Therapeutics is a biotechnology company pursuing vision-restoring engineered cell-based therapeutics.

Biotechnology · Camborne$150.0M Debt Financing
Janux Therapeutics
December 2024

Janux Therapeutics develops immunotherapies that generates immune responses to prevent tumors and not affecting a patient’s healthy tissue.

Biotechnology · La Jolla$350.0M Post-IPO Equity
Ottimo Pharma
December 2024

Ottimo Pharma develops innovative cancer therapies using PD1-VEGFR2 antibodies.

Biotechnology · Sandwich$140.0M Series A
Athira Pharma
December 2025

Athira Pharma is a clinical stage drug development company that specializes in biotechnology and pharmaceutical.

Biotechnology · Seattle$90.0M Post-IPO Equity
CAMP4 Therapeutics
December 2025

CAMP4 Therapeutics is a biotechnology company that uses RNA to restore healthy gene expression.

Biopharma · Cambridge$30.0M Post-IPO Equity
Yarrow
December 2025

Yarrow is developing a first-in-class antibody targeting TSHR for the treatment of Graves’ disease and thyroid eye disease.

Business Intelligence · New York$200.0M Venture - Series Unknown
Ambros Therapeutics
December 2025

Ambros Therapeutics is a clinical-stage biotechnology company.

Biotechnology · Irvine$125.0M Series A
CG Oncology
December 2024

CG Oncology is a clinical-stage biopharmaceutical company focused on the development of oncolytic immunotherapies to combat cancer.

Biotechnology · Irvine$238.0M Post-IPO Equity
nChroma Bio
December 2024

nChroma Bio is a cutting-edge biotechnology business that is developing targeted in vivo delivery systems as well as best-in-class cargo.

Biotechnology · Boston$75.0M Venture - Series Unknown
New Amsterdam Pharma
December 2024

New Amsterdam is a clinical-stage company focused on the research and development of transformative therapies for cardio-metabolic diseases.

Biotechnology · Naarden$452.6M Post-IPO Equity
Kymera Therapeutics
December 2025

Kymera Therapeutics is a biotechnology company that specializes in the field of targeted protein degradation.

Biotechnology · Cambridge$602.0M Post-IPO Equity
BlossomHill Therapeutics
December 2025

BlossomHill Therapeutics is a biopharmaceutical company focusing on oncology and autoimmune disorders.

Biopharma · San Diego$84.0M Series B
Think Bioscience
January 2026

Think Bioscience is reimagining synthetic biology by guiding the design and assembly of better medicines through the use of living systems.

Biotechnology · Boulder$55.0M Series A
Caldera Therapeutics
January 2026

Caldera Therapeutics is a biotech company engaged in the development of bispecific antibody CLD-423 for inflammatory bowel disease (IBD).

Biopharma · Cambridge$37.5M Series A
Sonoma Biotherapeutics
November 2025

Sonoma Biotherapeutics develops engineered regulatory T-cell (Treg) therapies to treat autoimmune and inflammatory diseases.

Biotechnology · South San Francisco$300K Grant
Quell Therapeutics
November 2021

Quell Therapeutics is a cell therapy company

Association · London$156.0M Series B
Pasithea Therapeutics
November 2025

Pasithea Therapeutics is a biotechnology company that seeks to solve clinical problems such as mental health.

Biotechnology · Miami Beach$60.0M Post-IPO Equity
Verve Therapeutics
November 2023

Verve Therapeutics is a clinical-stage biotechnology company developing genetic medicines for cardiovascular disease.

Biotechnology · Boston$143.8M Post-IPO Equity
35Pharma
November 2024

35Pharma is a biopharmaceutical company that designs and develops innovative biologics for diseases of high unmet medical need.

Biopharma · Montreal$53.0M Series C

Where Janus Henderson Investors invests

Biotechnology23
Therapeutics11
Health Care10
Pharmaceutical9
Life Science7
Medical7

About Janus Henderson Investors's portfolio

How many companies has Janus Henderson Investors invested in?

Janus Henderson Investors has invested in 227 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Janus Henderson Investors invest in?

Janus Henderson Investors's top investment sectors include Biotechnology, Therapeutics, Health Care, Pharmaceutical, Life Science. The firm invests across 15 different industry categories.

What is Janus Henderson Investors's largest investment?

Among tracked funding rounds, Structure Therapeutics received $747.5M in a Post-IPO Equity round. Janus Henderson Investors's total known invested capital is $31.3B.

What is the average investment size for Janus Henderson Investors?

Janus Henderson Investors's average investment size is $160.4M across its portfolio of 227 companies.

What are Janus Henderson Investors's most recent investments?

Recent Janus Henderson Investors portfolio additions include Diagonal Therapeutics, Phathom Pharmaceuticals, Synthekine, Vaxcyte, Structure Therapeutics. These companies were founded in 2020 or later.

Reach the founders behind these 227 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →